New belly fat injection cuts dangerous fat surrounding organs by 12% in early human trial
CBL-514 injection triggers apoptosis only in fat cells to reduce visceral fat by 12% in early trials, with implications for insulin resistance.
TL;DR
- An experimental injection, CBL-514, is being tested for its ability to reduce deadly visceral fat.
- Visceral fat is located deep in the abdomen and is linked to metabolism issues, insulin resistance, type 2 diabetes, and heart failure.
- Phase 2 trials showed that CBL-514 reduced subcutaneous fat, and MRI scans indicated a decrease in visceral fat compared to a placebo.
- Participants received injections of CBL-514 into their lower abdomen every three weeks for up to 12 weeks.
- The injection works by selectively triggering apoptosis (self-destruction) in fat cells.
- Four weeks after the final treatment, the average fat volume lowered by 12.01% in the CBL-514 group, while it increased by 5.68% in the placebo group.
- Beyond cosmetic benefits, the injection's ability to reduce visceral fat, body weight, and improve blood pressure and cholesterol is crucial for overall health.
- Unlike liposuction, CBL-514 can reduce visceral fat and its associated health risks.